Newsroom

START Doses First U.S. Patient in Moderna’s Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

Major study milestone highlights START’s commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials The START Center for Cancer Research (“START”), the world’s largest early-phase community-based oncology site network, today announced the dosing of the first U.S. participant in Moderna’s Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in […]

START Doses First U.S. Patient in Moderna’s Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors Read More »

CURC

START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center

START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary (GU) oncology. This acquisition strengthens

START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center Read More »

Malignant Hematology

The START Center for Cancer Research Expands its Capabilities to Support Early-Phase Hematological Cancer Trials

Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies 10 December 2024 The START Center for Cancer Research (“START”), the world’s largest community-based early phase cancer trial site network, has announced the expansion of its capabilities to support early phase hematological cancer trials globally. This expansion

The START Center for Cancer Research Expands its Capabilities to Support Early-Phase Hematological Cancer Trials Read More »

Rioja

The START Center for Cancer Research and Fundación Rioja Salud Announce New Partnership to Further Expand Access to Early Phase Clinical Trials in Spain

28 October 2024 The START Center for Cancer Research (“START”), a global leader in early-phase cancer clinical trials, today announced a new strategic partnership with the Fundación Rioja Salud, a foundation dedicated to (i) the promotion and protection of health, (ii) the training, teaching, research, development and innovation of Health Sciences and biotechnology, what includes

The START Center for Cancer Research and Fundación Rioja Salud Announce New Partnership to Further Expand Access to Early Phase Clinical Trials in Spain Read More »

START Dublin Building

First Dedicated Early Phase Oncology Clinical Trials Unit in Ireland opened by Minister Donohoe at the Mater Hospital

START Dublin will offer patients with advanced cancer the opportunity to participate in cutting edge research and enhance the availability of new cancer drugs 14 October 2024 The Minister for Public Expenditure, NDP Delivery and Reform, Paschal Donohoe TD has today (Monday) officially opened START Dublin, the Republic of Ireland’s first dedicated Phase I Clinical

First Dedicated Early Phase Oncology Clinical Trials Unit in Ireland opened by Minister Donohoe at the Mater Hospital Read More »

Dr. Amita Patnaik

START’s Amita Patnaik, MD, FRCPC: One of PharmaVoice’s 100 Most Inspiring Leaders of 2024

San Antonio, TX – October 8, 2024. The START Center for Cancer Research (“START”) proudly announces that Amita Patnaik, MD, FRCPC, has been named to the prestigious PharmaVoice 100 list as a “Cancer Care Visionary.” This annual award celebrates inspiring individuals in life sciences who are making a profound impact on the field and driving

START’s Amita Patnaik, MD, FRCPC: One of PharmaVoice’s 100 Most Inspiring Leaders of 2024 Read More »

Chris Takimoto

The START Center for Cancer Research Appoints Dr. Chris Takimoto as Chief Medical Officer

Dr. Takimoto to propel scientific and medical strategies and advance START’s leadership in global early-phase cancer research San Antonio, TX – October 2, 2024. The START Center for Cancer Research (“START”) proudly announces the appointment of Chris H. Takimoto, MD, PhD, FACP, as its new Chief Medical Officer. Dr. Takimoto, a renowned physician-scientist, oncology drug

The START Center for Cancer Research Appoints Dr. Chris Takimoto as Chief Medical Officer Read More »

Power of Community Site Networks

START Announces Launch of Virtual Panel Series: “The Power of Community Site Networks: Advancing Science & Broadening Access to Early Phase Cancer Trials”

New Series Unites Global Experts to Explore the Future of Oncology Research in Community Settings San Antonio, TX – August 29, 2024. The START Center for Cancer Research (“START”), the largest global network of fully dedicated, community-based, early-phase oncology clinical trial sites, is proud to announce the launch of its Virtual Panel Series, titled “The

START Announces Launch of Virtual Panel Series: “The Power of Community Site Networks: Advancing Science & Broadening Access to Early Phase Cancer Trials” Read More »

Zuckerberg Cancer Institute at Northwell

Northwell Health and The START Center for Cancer Research to Form Strategic Partnership, Increasing Patient Access to Breakthrough Cancer Research

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute New Hyde Park, NY / San Antonio, TX – May 31, 2024.  Northwell Health, New York State’s largest health care provider, and The START Center for Cancer Research (“START”), renowned for being the largest global network of fully dedicated, community-based, early-phase

Northwell Health and The START Center for Cancer Research to Form Strategic Partnership, Increasing Patient Access to Breakthrough Cancer Research Read More »

ASCO-2024-Annual

Leading the Charge in Early Phase Oncology Trials: START’s Impact at the ASCO 2024 Annual Meeting

The START Center for Cancer Research (“START”) is set to have a significant presence at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Known for our commitment to the advancement of cancer research and treatment, we are excited to share that our team of Principal Investigators (PIs) will be involved in nearly 100

Leading the Charge in Early Phase Oncology Trials: START’s Impact at the ASCO 2024 Annual Meeting Read More »